Merck Net Income 2010-2022 | MRK

Merck annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Merck net income for the quarter ending March 31, 2022 was $4.310B, a 35.58% increase year-over-year.
  • Merck net income for the twelve months ending March 31, 2022 was $14.180B, a 101.79% increase year-over-year.
  • Merck annual net income for 2021 was $13.049B, a 84.65% increase from 2020.
  • Merck annual net income for 2020 was $7.067B, a 28.2% decline from 2019.
  • Merck annual net income for 2019 was $9.843B, a 58.25% increase from 2018.
Merck Annual Net Income
(Millions of US $)
2021 $13,049
2020 $7,067
2019 $9,843
2018 $6,220
2017 $2,394
2016 $3,920
2015 $4,442
2014 $11,920
2013 $4,404
2012 $6,165
2011 $6,257
2010 $859
2009 $12,853
Merck Quarterly Net Income
(Millions of US $)
2022-03-31 $4,310
2021-12-31 $3,758
2021-09-30 $4,567
2021-06-30 $1,545
2021-03-31 $3,179
2020-12-31 $-2,095
2020-09-30 $2,941
2020-06-30 $3,002
2020-03-31 $3,219
2019-12-31 $2,357
2019-09-30 $1,901
2019-06-30 $2,670
2019-03-31 $2,915
2018-12-31 $1,827
2018-09-30 $1,950
2018-06-30 $1,707
2018-03-31 $736
2017-12-31 $-1,047
2017-09-30 $-56
2017-06-30 $1,946
2017-03-31 $1,551
2016-12-31 $-594
2016-09-30 $2,184
2016-06-30 $1,205
2016-03-31 $1,125
2015-12-31 $976
2015-09-30 $1,826
2015-06-30 $687
2015-03-31 $953
2014-12-31 $7,316
2014-09-30 $895
2014-06-30 $2,004
2014-03-31 $1,705
2013-12-31 $781
2013-09-30 $1,124
2013-06-30 $906
2013-03-31 $1,593
2012-12-31 $908
2012-09-30 $1,729
2012-06-30 $1,792
2012-03-31 $1,736
2011-12-31 $1,505
2011-09-30 $1,689
2011-06-30 $2,020
2011-03-31 $1,043
2010-12-31 $-534
2010-09-30 $342
2010-06-30 $752
2010-03-31 $299
2009-12-31 $6,447
2009-09-30 $3,424
2009-06-30 $1,556
2009-03-31 $1,425
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $236.570B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.705B 17.91
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07